** Shares of drug developer vTv Therapeutics VTVT.O rise 19.2% to $17.70, their biggest one-day percentage win in more than one year

** Co says U.S. FDA has lifted clinical hold on development of cadisegliatin, an oral adjunctive therapy to insulin therapy for treatment of type 1 diabetes

** Co plans to resume its late-stage trial for the therapy after submitting protocol amendment to shorten trial from 12 to 6 months

** Up to last close, stock down 12.9% in last 12 months

(Reporting by Christy Santhosh)

((Christy.Santhosh@thomsonreuters.com))